Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases

 
• By Mandy Jackson
  
businessman and businesswoman are shaking hands and exchanging folder after agreement was reached
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business